Gilead Sciences (GILD) Misses Q4 EPS by 4c; offers guidance

Gilead Sciences (NASDAQ: GILD) reported Q4 EPS of $1.72, $0.04 worse than the analyst estimate of $1.76. Revenue for the quarter came in at $7.1 billion versus the consensus estimate of $7.1 billion.

GUIDANCE:

Gilead Sciences sees FY2024 EPS of $6.85-$7.25, versus the consensus of $7.19. Gilead Sciences sees FY2024 revenue of $27.1-27.5 billion, versus the consensus of $27.632 billion.

For earnings history and earnings-related data on Gilead Sciences (GILD) click here.

You May Also Be Interested In

• Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
• Ecolab pops as Citi sees improving setup into Q2 earnings
• European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors